Revelation Biosciences (REVB) Change in Accured Expenses (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Change in Accured Expenses of $604341.0 for Q4 2025, up 212.44% year-over-year from $193428.0 in Q4 2024, and up 1027.73% quarter-over-quarter from $53589.0 in Q3 2025.
Revelation Biosciences (REVB) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Change in Accured Expenses for 6 consecutive years, with $604341.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 212.44% year-over-year to $604341.0; the TTM figure through Dec 2025 stood at $269756.0 (up 109.19% YoY), while the FY2025 annual figure was $269756.0, up 109.19% from the prior year.
- Change in Accured Expenses rose to $604341.0 in Q4 2025 per REVB's latest filing, from $53589.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.3 million in Q2 2024 and bottomed at -$8.9 million in Q3 2024.
- Historically, Change in Accured Expenses has averaged -$95569.7 across 5 years, with a median of $82957.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 1585.35% — and 2024, when it plunged 34928.53%.
- Revelation Biosciences' Change in Accured Expenses stood at $378470.0 in 2021, then sank by 106.35% to -$24050.0 in 2022, then surged by 567.05% to $112325.0 in 2023, then jumped by 72.2% to $193428.0 in 2024, then soared by 212.44% to $604341.0 in 2025.
- Business Quant data shows REVB's Change in Accured Expenses at $604341.0 in Q4 2025, $53589.0 in Q3 2025, and $275994.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 604,341.00 |
| Dec 31, 2025 | 604,341.00 |
| Sep 30, 2025 | 53,589.00 |
| Sep 30, 2025 | 53,589.00 |
| Jun 30, 2025 | 275,994.00 |
| Jun 30, 2025 | 275,994.00 |
| Mar 31, 2025 | -664,168.00 |
| Mar 31, 2025 | -664,168.00 |
| Dec 31, 2024 | 193,428.00 |
| Dec 31, 2024 | 193,428.00 |
| Sep 30, 2024 | -8.90 Mn |
| Sep 30, 2024 | -8.90 Mn |
| Jun 30, 2024 | 6.31 Mn |
| Jun 30, 2024 | 6.31 Mn |
| Mar 31, 2024 | -532,180.00 |
| Mar 31, 2024 | -532,180.00 |
| Dec 31, 2023 | 112,325.00 |
| Dec 31, 2023 | 112,325.00 |
| Sep 30, 2023 | 525,165.00 |
| Sep 30, 2023 | 525,165.00 |